Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug development for the treatment of RyR1-related skeletal muscle diseases.

Current opinion in pharmacology - 1 Apr 2023

Murayama Takashi, Kurebayashi Nagomi, Ishida Ryosuke, Kagechika Hiroyuki

Abstract excerpt

Type 1 ryanodine receptor (RyR1) is an intracellular Ca2+ release channel on the sarcoplasmic reticulum of skeletal muscle, and it plays a central role in excitation-contraction (E-C) coupling. Mutations in RyR1 are implicated in various muscle diseases including malignant hyperthermia, central core disease, and myopathies. Currently, no specific treatment exists for most of these diseases. Recently,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcium
Share to Calcium Signaling
Share to Drug Development

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscle, Skeletal

Share to Muscular Diseases

Share to Mutation

Share to Ryanodine Receptor Calcium Release Channel

Source

Identifiers

PMID: 36842386
DOI: 10.1016/j.coph.2023.102356

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug development for the treatment of RyR1-related skeletal muscle diseases.PMID 36842386Read ↗

A reconstituted depolarization-induced Ca2+ release platform for validation of skeletal muscle disease mutations and drug discovery.Semantic proximity Read ↗

Efficient High-Throughput Screening by Endoplasmic Reticulum Ca2+ Measurement to Identify Inhibitors of Ryanodine Receptor Ca2+-Release Channels.Semantic proximity Read ↗

Reconstituted depolarization-induced Ca <sup>2+</sup> release platform for skeletal muscle disease mutation validation and drug discoverySemantic proximity Read ↗

Ryanodine receptor channelopathies.Semantic proximity Read ↗

Update on RYR1-related myopathies.Semantic proximity Read ↗

The ryanodine receptor: a pivotal Ca2+ regulatory protein and potential therapeutic drug target.Semantic proximity Read ↗

Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region.Semantic proximity Read ↗

Review of RyR1 pathway and associated pathomechanismsSemantic proximity Read ↗

Therapies for RYR1-Related Myopathies: Where We Stand and the Perspectives.Semantic proximity Read ↗

Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.Semantic proximity Read ↗

Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.Semantic proximity Read ↗

Ryanodine receptor 1 ( <i>RYR1</i> ) patient-derived muscle cells recapitulate disease phenotypes in 2D and 3D culture modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.